159 related articles for article (PubMed ID: 34569167)
1. Risedronate use to attenuate bone loss following sleeve gastrectomy: Results from a pilot randomized controlled trial.
Beavers KM; Beavers DP; Fernandez AZ; Greene KA; Swafford AA; Weaver AA; Wherry SJ; Ard JD
Clin Obes; 2021 Dec; 11(6):e12487. PubMed ID: 34569167
[TBL] [Abstract][Full Text] [Related]
2. Sequential Therapy With Recombinant Human IGF-1 Followed by Risedronate Increases Spine Bone Mineral Density in Women With Anorexia Nervosa: A Randomized, Placebo-Controlled Trial.
Haines MS; Kimball A; Meenaghan E; Bachmann KN; Santoso K; Eddy KT; Singhal V; Ebrahimi S; Dechant E; Weigel T; Ciotti L; Keane RJ; Gleysteen S; Mickley D; Bredella MA; Tan CO; Gupta R; Misra M; Schoenfeld D; Klibanski A; Miller KK
J Bone Miner Res; 2021 Nov; 36(11):2116-2126. PubMed ID: 34355814
[TBL] [Abstract][Full Text] [Related]
3. The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial.
Sköldenberg OG; Salemyr MO; Bodén HS; Ahl TE; Adolphson PY
J Bone Joint Surg Am; 2011 Oct; 93(20):1857-64. PubMed ID: 22012522
[TBL] [Abstract][Full Text] [Related]
4. Risedronate use may blunt appendicular lean mass loss secondary to sleeve gastrectomy: Results from a pilot randomized controlled trial.
Flores LE; Beavers KM; Beavers DP; Greene KA; Madrid DA; Miller RM; Ard JD; Bilek LD; Weaver AA
JCSM Rapid Commun; 2023; 6(1):18-25. PubMed ID: 37273449
[TBL] [Abstract][Full Text] [Related]
5. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
van Bodegraven AA; Bravenboer N; Witte BI; Dijkstra G; van der Woude CJ; Stokkers PC; Russel MG; Oldenburg B; Pierik M; Roos JC; van Hogezand RA; Dik VK; Oostlander AE; Netelenbos JC; van de Langerijt L; Hommes DW; Lips P;
Gut; 2014 Sep; 63(9):1424-30. PubMed ID: 24146170
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of risedronate with cholecalciferol on bone mineral density in Korean patients with osteoporosis.
Park SY; Kang MI; Park HM; Rhee Y; Moon SH; Yoon HK; Koh JM; Chang JS; Kim IJ; Won YY; Park YS; Choi H; Shin CS; Yoon TR; Yun SC; Chung HY;
Arch Osteoporos; 2019 Dec; 15(1):3. PubMed ID: 31820121
[TBL] [Abstract][Full Text] [Related]
7. Risedronate to Prevent Bone Loss After Sleeve Gastrectomy: Study Design and Feasibility Report of a Pilot Randomized Controlled Trial.
Swafford AA; Ard JD; Beavers DP; Gearren PC; Fernandez AZ; Ford SA; Greene KA; Kammire DE; Nesbit BA; Reed KK; Weaver AA; Beavers KM
JBMR Plus; 2020 Oct; 4(10):e10407. PubMed ID: 33103032
[TBL] [Abstract][Full Text] [Related]
8. Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial.
Mok CC; Tong KH; To CH; Siu YP; Ma KM
Osteoporos Int; 2008 Mar; 19(3):357-64. PubMed ID: 18038273
[TBL] [Abstract][Full Text] [Related]
9. Strategies to reduce the onset of sleeve gastrectomy associated bone loss (STRONG BONES): Trial design and methods.
Stapleton JR; Ard JD; Beavers DP; Cogdill LS; Fernandez AZ; Howard MJ; Justice JN; Lynch SD; Newman JJ; Weaver AA; Beavers KM
Contemp Clin Trials Commun; 2023 Aug; 34():101181. PubMed ID: 37456507
[TBL] [Abstract][Full Text] [Related]
10. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
Saag KG; Pannacciulli N; Geusens P; Adachi JD; Messina OD; Morales-Torres J; Emkey R; Butler PW; Yin X; Lems WF
Arthritis Rheumatol; 2019 Jul; 71(7):1174-1184. PubMed ID: 30816640
[TBL] [Abstract][Full Text] [Related]
11. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
[TBL] [Abstract][Full Text] [Related]
12. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571
[TBL] [Abstract][Full Text] [Related]
14. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.
Greenspan SL; Brufsky A; Lembersky BC; Bhattacharya R; Vujevich KT; Perera S; Sereika SM; Vogel VG
J Clin Oncol; 2008 Jun; 26(16):2644-52. PubMed ID: 18427147
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sodium RISedronate for glucocorticoid-induced OsTeoporosis with rheumaTOid arthritis (RISOTTO study): A multicentre, double-blind, randomized, placebo-controlled trial.
Fujieda Y; Horita T; Nishimoto N; Tanimura K; Amasaki Y; Kasahara H; Furukawa S; Takeda T; Fukaya S; Matsui K; Tsutsumi A; Furusaki A; Sagawa A; Katayama K; Takeuchi K; Katsumata K; Kurita T; Shane P; Kato M; Oku K; Yasuda S; Takahata M; Iwasaki N; Atsumi T
Mod Rheumatol; 2021 May; 31(3):593-599. PubMed ID: 32820698
[TBL] [Abstract][Full Text] [Related]
16. Effects of Roux-en-Y gastric bypass and sleeve gastrectomy on bone mineral density and marrow adipose tissue.
Bredella MA; Greenblatt LB; Eajazi A; Torriani M; Yu EW
Bone; 2017 Feb; 95():85-90. PubMed ID: 27871812
[TBL] [Abstract][Full Text] [Related]
17. The effect of excessive fat tissue on the measure of bone mineral density by dual X-ray absorptiometry: the impact of substantial weight loss following sleeve gastrectomy.
Maïmoun L; Mariano-Goulart D; Jaussent A; Lefebvre P; Picot MC; Mahadea K; Boudousq V; Fouillade C; Nocca D; Ben Bouallègue F
Clin Physiol Funct Imaging; 2019 Sep; 39(5):345-354. PubMed ID: 31090241
[TBL] [Abstract][Full Text] [Related]
18. Protocol for a pilot randomised controlled trial of zoledronic acid to prevent bone loss following sleeve gastrectomy surgery.
Flores LE; Mack L; Wichman C; Weaver AA; Kothari V; Bilek LD
BMJ Open; 2021 Dec; 11(12):e057483. PubMed ID: 34887285
[TBL] [Abstract][Full Text] [Related]
19. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.
Saag KG; Wagman RB; Geusens P; Adachi JD; Messina OD; Emkey R; Chapurlat R; Wang A; Pannacciulli N; Lems WF
Lancet Diabetes Endocrinol; 2018 Jun; 6(6):445-454. PubMed ID: 29631782
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
Reid DM; Devogelaer JP; Saag K; Roux C; Lau CS; Reginster JY; Papanastasiou P; Ferreira A; Hartl F; Fashola T; Mesenbrink P; Sambrook PN;
Lancet; 2009 Apr; 373(9671):1253-63. PubMed ID: 19362675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
